Informaciones
Psiquiátricas
2014-n.º 216
43
EVOLUCIÓN DEL DETERIORO COGNITIVO ASOCIADO A TRASTORNO MENTAL SEVERO
7. Heinrichs RW & Zakzanis KK. Neurocog-
nitive deficit in schizophrenia: a quanti-
tative review of the evidence. Neuropsy-
chology, 1998;12(3): 426-45.
8. Keefe RS E & Harvey PD. Novel Antis-
chizophrenia Treatments, 2012; 213,
11–37.
9. Laukka EJ, Lövdén M, Herlitz A, Karls-
son S, Ferencz B, Pantzar A, Bäckman
L. Genetic effects on old-age cognitive
functioning: a population-based study.
Psychology and aging, 2013;28(1):262-
74.
10. Lin H C, Hsiao F H, Pfeiffer S, Hwang Y
T & Lee HC. (2008). An increased risk
of stroke among young schizophrenia
patients. Schizophrenia research, 101(1-
3):234-41.
11. Lindenmayer JP, Khan A, Kaushik S,
Thanju A, Praveen R, Hoffman L, Wance
D. Relationship between metabolic
syndrome and cognition in patients with
schizophrenia. Schizophrenia research,
2012;142(1-3):171-6.
12. Loewenstein DA, Czaja SJ, Bowie CR &
Harvey PD. Age-associated differences in
cognitive performance in older patients
with schizophrenia: a comparison with
healthy older adults. The American
journal of geriatric psychiatry : official
journal of the American Association for
Geriatric Psychiatry, 2012;20(1):29-40.
13. McCrimmon RJ, Ryan CM & Frier BM. Dia-
betes and cognitive dysfunction. Lancet,
2012;379 (9833):2291-9.
14. McEvoy JP, Meyer JM, Goff DC, Nasrallah
H a, Davis SM, Sullivan L, Lieberman J.
a. Prevalence of the metabolic syndrome
in patients with schizophrenia: baseline
results from the Clinical Antipsychotic
Trials of Intervention Effectiveness
(CATIE) schizophrenia trial and com-
parison with national estimates from
NHANES III. Schizophrenia research,
2005;80(1): 19–32. doi:10.1016/j.
schres.2005.07.014
15. Millan MJ, Agid Y, Brüne M, Bullmore ET,
Carter CS, Clayton NS, Young LJ. Cogniti-
ve dysfunction in psychiatric disorders:
characteristics, causes and the quest for
improved therapy. Nature reviews. Drug
discovery, 2012;11(2):141-68.
16. Napal O, Ojeda N, Sánchez P, Elizagára-
te E, Peña J, Ezcurra J & Gutiérrez M.
The course of the schizophrenia and its
impact on cognition: a review of lite-
rature. Actas españolas de psiquiatría,
2012;40(4):198-220.
17. Nasrallah H a Meyer JM, Goff DC, McEvoy
JP, Davis SM, Stroup TS & Lieberman J.
a. Low rates of treatment for hyper-
tension, dyslipidemia and diabetes in
schizophrenia: data from the CATIE
schizophrenia trial sample at baseline.
Schizophrenia research, 2006;86(1-
3):15-22.
18. Nielsen RE, Uggerby AS, Jensen SOW &
McGrath JJ. Increasing mortality gap for
patients diagnosed with schizophrenia
over the last three decades--a Danish
nationwide study from 1980 to 2010.
Schizophrenia research, 2013;146(1-
3):22-7.
19. Nyberg L, Lövdén M, Riklund K, Linden-
berger U & Bäckman L. Memory aging
and brain maintenance. Trends in cogni-
tive sciences, 2012;16(5):292-305.
